Objective To explore the efficacy of levosimendan combined with valsartan and trmetazidine in patients with heart fail-ure(HF).Method 85 HF patients admitted to Qinzhou Second People's Hospital from March 2023 to February 2024 were included,they were divided into the control group 42 cases and the study group 43 cases by random touch ball method.The control group was treated with sacubaprotrosovalsartan combined with trimetazidine,and the study group was combined with levosimendan.Comparing the two groups of clinical efficacy,cardiac function[left ventricular end-systolic inner diameter(Left Ventricular End-Systolic Diameter,LVESD),left ventricular ejection fraction(Left Ventricular Ejection Fraction,LVEF),LV short axis shortening rate(Fractional Shortening,FS),left ventricular diastolic inner diameter(Left Ventricular End-Diastolic Diameter,LVEDD)],markers of myocardial injury[creatine kinase(creatine kinase,CK),creatine kinase isozymes(creatine kinase isoenzymes,CK-MB),Troponin I(cardiac troponin I,The cTnI),BNP peptide(brain natriuretic peptide,BNP)],adverse effects[abdominal pain,diarrhea,skin rash].Re-sults The total effective rate of clinical treatment in the study group was 97.67%,which was higher than the control group's 85.71%,and the difference was statistically significant(P＜0.05).There was no statistically significant difference in heart function levels be-tween the two groups before treatment(P＞0.05);After treatment,the levels of LVESD and LVEDD in the study group were lower than those in the control group,while the levels of LVEF and FS were higher than those in the control group,with statistical significance(P＜0.05).There was no statistically significant difference in the levels of myocardial injury markers between the two groups before treat-ment(P＞0.05);After treatment,the levels of myocardial injury markers in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Levosimendan combined with sacuvalsartan and trimetazidine has high clinical efficacy,can improve cardiac function,reduce the level of myocardial injury markers,and low risk of adverse effects.
维普
万方数据
